{"id":22230,"date":"2023-02-06T13:55:00","date_gmt":"2023-02-06T05:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22230"},"modified":"2025-01-20T13:58:26","modified_gmt":"2025-01-20T05:58:26","slug":"gilead-sciences-reports-q4-and-full-year-2022-financial-results","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22230","title":{"rendered":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results"},"content":{"rendered":"\n<p>US major Gilead Sciences, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD 26.0 billion to USD 26.5 billion.<\/p>\n\n\n\n<p><strong>CEO&#8217;s Perspective on Performance<\/strong><br>CEO Daniel O\u2019Day viewed the year\u2019s performance positively, describing it as &#8220;Gilead\u2019s strongest full-year growth \u2026 since HCV sales peaked in 2015.&#8221; This included growing strength for the firm\u2019s oncology portfolio, which saw sales increase 71% to exceed USD 2.1 billion over the 12 months for the first time.<\/p>\n\n\n\n<p><strong>Oncology Portfolio Highlights<\/strong><br>Strong performers in the cancer segment were the two CD19 chimeric antigen receptor (CAR) T cell therapies, Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel), generating growth of 68% YOY to USD 1.5 billion in full-year sales. The TROP-2 targeted antibody drug conjugate (ADC) Trodelvy (sacituzumab govitecan) also performed well, generating USD 680 million over the 12 months, up 79% YOY as uptake continued to improve in Europe and the United States for the triple-negative breast cancer indication.<\/p>\n\n\n\n<p><strong>Other Product Performance<\/strong><br>Sales of COVID-19 therapy Veklury (remdesivir) fell -30% YOY to USD 3.9 billion. HIV portfolio sales were up 5% to USD 17.2 billion, including USD 10.4 billion for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide), which saw a 20% YOY increase.<\/p>\n\n\n\n<p><strong>Deal-Making and Strategic Collaborations<\/strong><br>Deal-making during the report period saw ongoing efforts to build Gilead\u2019s presence in the oncology field. These included a strategic collaboration between Gilead subsidiary Kite and US-based Arcellx Inc. (Nasdaq: ACLX) to co-develop and co-commercialize a BCMA-targeted CAR-T in late-stage development for multiple myeloma. Gilead is also moving to acquire Tmunity Therapeutics Inc., which will provide Kite with preclinical and clinical programs, including an \u201carmored\u201d CAR-T technology platform that has the potential to improve efficacy and accelerate manufacturing processes. Additionally, Gilead acquired the remaining rights to GS-1811, an anti-CCR8 antibody developed by Jounce for the treatment of solid tumors, and penned a collaboration and licensing agreement with EVOQ Therapeutics, Inc. to advance EVOQ\u2019s proprietary NanoDisc technology for the treatment of rheumatoid arthritis and lupus.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,226,1025],"class_list":["post-22230","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD 26.0 billion to USD 26.5 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T05:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T05:58:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results\",\"datePublished\":\"2023-02-06T05:55:00+00:00\",\"dateModified\":\"2025-01-20T05:58:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22230#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22230\",\"name\":\"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-06T05:55:00+00:00\",\"dateModified\":\"2025-01-20T05:58:26+00:00\",\"description\":\"US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD 26.0 billion to USD 26.5 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22230\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results - Insight, China&#039;s Pharmaceutical Industry","description":"US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD 26.0 billion to USD 26.5 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22230","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22230","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-06T05:55:00+00:00","article_modified_time":"2025-01-20T05:58:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results","datePublished":"2023-02-06T05:55:00+00:00","dateModified":"2025-01-20T05:58:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22230"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22230#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22230","url":"https:\/\/flcube.com\/?p=22230","name":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-06T05:55:00+00:00","dateModified":"2025-01-20T05:58:26+00:00","description":"US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD 26.0 billion to USD 26.5 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22230"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22230\/revisions"}],"predecessor-version":[{"id":22231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22230\/revisions\/22231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}